Major Pharmaceuticals Recalls 12 Levothyroxine Lines Nationwide Over Subpotency
Updated
Updated · WJXT News4JAX · Jul 27
Major Pharmaceuticals Recalls 12 Levothyroxine Lines Nationwide Over Subpotency
3 articles · Updated · WJXT News4JAX · Jul 27
Summary
Twelve Levothyroxine sodium tablet product lines in seven strengths — 25 mcg to 150 mcg — were voluntarily recalled nationwide after Major Pharmaceuticals found them subpotent.
Levothyroxine replaces thyroid hormone in hypothyroidism treatment, so reduced potency can leave patients under-treated and allow fatigue, weight gain, cold sensitivity and cognitive problems to persist or worsen.
The recall began July 13 and was classified by the FDA as Class II, meaning use could cause temporary or medically reversible health consequences while serious harm is considered remote.
Patients should check lot numbers on blister-carton packaging and contact a pharmacist or physician, while pharmacies and providers that distributed affected lots were told to quarantine remaining inventory.